Stay updated with breaking news from Vla2001. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
21st Austria weekly - Valneva Vienna Stock Exchange 30/12/2022 [pic1]Valneva: an Austrian/French specialty vaccine company reported further heterologous booster data from exploratory small clinical study for its inactivated COVID-19 vaccine VLA2001. The show that a dose of VLA2001 was well tolerated in previously BNT162b2 Pfizer/BioNTech- or mRNA 1273 Moderna-vaccinated participants confirming the favorable safety profile seen across all studies – including homologous settings. However this study additional elicited only marginally increased neutralizing antibody response. Company positive results following primary vaccination with ChAdOx1-S AstraZeneca August ....
21st Austria weekly - Valneva Pierer Mobility 16/09/2022 [pic1]Valneva: an Austrian/French specialty vaccine company and IDT Biologika today announced they have agreed to terminate their collaboration following the delivery of inactivated COVID-19 bulk considering current order levels existing inventories. In light reduced European Commission order Valneva has suspended manufacturing and as compensation will pay up Euro 36.2 mn in cash equivalent 4.5 kind form specified equipment purchased by Valneva.As per commercial services agreement signed November 2021 produced VLA2001 at its Biosafety Level ....
21st Austria weekly - Valneva Erste Group 16/06/2022 [pic1]Valneva: an Austrian/French specialty vaccine company today announced that it has entered into a settlement agreement with the Government of United Kingdom “HMG” in relation to termination supply for Valneva’s COVID-19 candidate VLA2001. The Company on September 13 2021 had received notice from HMG and termination which Valneva accepted basis HMG’s ....
21st Austria weekly - Valneva Andritz 16/05/2022 [pic1]Valneva: an Austrian/French specialty vaccine company announced that it has received a notice from the European Commission EC of intent to terminate advance purchase agreement APA for Valneva’s inactivated whole-virus COVID-19 candidate VLA2001. The APA provides EC with right if VLA2001 had not marketing authorization Medicines Agency ....